Advancing Breakthrough Therapeutics to Transform the Treatment of Neuronal Hypersensitivity Disorders
Who We Are
We are developing an innovative, small molecule for treatment of refractory chronic cough, with potential to expand into multiple high value indications, including neuropathic pain, migraine and hyperactive bladder.
Our Differentiated Approach
Targeting the Root Cause of Neuronal Hypersensitivity
Selectively inhibiting FAAH to increasing anandamide levels, reducing excessive sensory neurons activity to address the underlying cause rather than just the symptoms.
Peripheral Action Potentially Avoiding CNS Side Effects
Designed to work peripherally to target first-order sensory neurons and avoid centrally mediated side effects. This unique mechanism optimizes efficacy while enhancing safety and tolerability.
Broad Potential Across Multiple Indications
Potential applications in chronic cough, migraine headache, peripheral painful neuropathies and hyperactive bladder.
Our Development Pipeline
